February 25, 2019 05:29 AM ESTUpdated 07:57 AM

Biotech M&A is back. Ipsen set to fork out up to $1.3B for rare disease specialist Clementia

Natalie Grover

Reporter

Merger Monday is back in full swing. Along with Roche buying Spark Therapeutics $ONCE, Parisian biotech Ipsen (Euronext: $IPN) is beefing up its rare …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Biotech M&A is back. Ipsen set to fork out up to $1.3B for rare disease specialist Clementia

Natalie Grover

Reporter

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

A decade after its ill-fated $40.5B megadeal, Teva pivots from generics to innovation

Omada Health is going public on Friday at a $1.1B valuation

Biotech ranks as China’s best shot to surpass US in emerging tech, report finds

FDA's Makary looks at ways to speed drug approvals, talks about cutting user fees

Trump's health appointees pledge support for cell and gene therapies at FDA roundtable

Cytiva and EurekaBio form strategic partnership to advance lentiviral vector manufacturing for cell and gene therapy ...

Biotech M&A is back. Ipsen set to fork out up to $1.3B for rare dis­ease spe­cial­ist Clemen­tia

Reporter

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Biotech M&A is back. Ipsen set to fork out up to $1.3B for rare disease specialist Clementia